Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis

Shenzhen Hornetcorn Biotechnology

Status and phase

Unknown

Phase 1

Conditions

Pneumoconiosis

Treatments

Biological: Human umbilical cord mesenchymal stem cells

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02790762

HYK-pneumoconiosis

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Pneumoconiosis.

Full description

Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into mature cells typical of several tissues, which have been confirmed in in vivo and in vitro experiments.

To investigate the effects of hUC-MSC treatment for Pneumoconiosis, 10 patients with Pneumoconiosis will be enrolled and receive 4 times of hUC-MSC transplantation.

Enrollment

10 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient who have signed the informed consent document;
Clinical and radiological evidence of liver cirrhosis.

Exclusion criteria

Pregnant women or lactating mothers;
History of neurological disease, head injury or psychiatric disorder;
Patients with positive human immunodeficiency (HIV) at screening indicative of current of pass infection;
With malignant tumors;
Abnormal blood coagulation, combine other tumor or special condition;
Patients who had participated in other clinical trials within three months prior to this study.